REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC. (REGN) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The R&D Factory: This isn't a gamble on a single molecule; it's an investment in a system. The "VelociSuite" is a proprietary discovery engine that lowers the cost of failure and accelerates the path to market. It is the "toll bridge" for biological discovery.
• The Partnership Arbitrage: Regeneron captures the high-margin upside of discovery while outsourcing the grueling, capital-intensive global distribution to partners. This allows them to maintain a leaner corporate structure than the "Big Pharma" dinosaurs.
• High-Barrier Biologicals: Unlike small-molecule generics, biologics are harder to copy. The "legal hammer" of their IP is reinforced by the sheer complexity of manufacturing these drugs.
• The Price of Admission: To be a Berkshire-grade investment, we need to stop paying for hope and start paying for certainty. It becomes attractive when the market prices it as a dying legacy business rather than a growth engine—likely in the $500–$600 range.

🐻 The Bear Case (Charlie inverts)

“Show me where I’ll die and I won’t go there.”

• The Patent Cliff & Biosimilar Erosion: The business is dangerously over-reliant on a few blockbuster pipes (Eylea). If biosimilars breach the moat faster than VelociSuite produces new winners, the revenue doesn't just dip—it evaporates.
• The Efficiency Trap: The numbers tell a grim story. ROE falling from 20.1% to 14.4% while margins collapse from 90.9% to 31.4% is a textbook definition of diseconomies of scale. They are spending more to earn less.
• The Regulatory Guillotine: The US government (via the Inflation Reduction Act) is now the primary buyer. If Medicare mandates aggressive price ceilings on their top biologicals, the "IP moat" becomes a paper tiger.
• Most Likely Failure: A "Double Whammy" of Eylea revenue decay combined with a string of Phase III trial failures over the next 3–5 years.

💰 Valuation & Margin of Safety

The DCF is a mathematical exercise; the financials are a warning sign.

• Intrinsic value estimate: $883.53 per share.
• 25% margin of safety entry: $662.65 (Conservative).
• 50% margin of safety entry: $441.77 (Buffett's ideal).
• Current Status: Fairly valued to Expensive. While the DCF suggests value, the $3.6B drop in Net Income since 2021 suggests the "intrinsic value" is based on a version of the company that no longer exists.

Verdict: PASS

The decay in ROE and margins suggests the business is losing its grip on efficiency. We do not buy "roller coasters," and the current volatility in Net Income is too severe to ignore. Unless the price drops to the $440 level to compensate for the structural risks, we stay on the sidelines.